BB Biotech Reports Strong Q2 Results with 17.2% NAV Increase

BB Biotech (BION) has published its Q2 results, showing a NAV increase of 17.2% in Swiss franc terms.

This performance was ahead of the benchmark by 3.5 percentage points and led to a rise in the share price of 9.7%.

The discount on BION widened to 12.9%, but this did not deter the company, which saw strong clinical execution and continued M&A activity driving its progress.

Bion's portfolio evolved significantly with the addition of 12 new investments, bringing the total to 39.